Legend Biotech Prices Public Offering of ADSs
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Source: Newsfilter
- Offering Size: Legend Biotech has priced its public offering of 7,700,000 American Depositary Shares (ADSs) at $29.35 each, aiming for gross proceeds of approximately $226 million, reflecting strong market demand for its cell therapies.
- Underwriter Selection: Morgan Stanley, Jefferies, Citigroup, and Deutsche Bank are serving as joint book-running managers for the offering, indicating the company's credibility and attractiveness in the capital markets, further solidifying its leadership in the cell therapy sector.
- Additional Option: The company has granted underwriters a 30-day option to purchase an additional 1,155,000 ADSs at the same price, a strategy that could enhance total fundraising and increase financial flexibility.
- Market Outlook: The offering is expected to close on June 23, 2026, and if successful, will provide funding for Legend Biotech's future innovations and expansions, supporting its ongoing development in the CAR-T cell therapy space.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LEGN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LEGN
Wall Street analysts forecast LEGN stock price to rise
11 Analyst Rating
10 Buy
1 Hold
0 Sell
Strong Buy
Current: 33.380
Low
48.00
Averages
68.10
High
90.00
Current: 33.380
Low
48.00
Averages
68.10
High
90.00
About LEGN
Legend Biotech Corporation is a global biopharmaceutical company. The Company is engaged in the discovery, development, manufacturing and commercialization of cell therapies for oncology and other indications. Its lead product candidate, ciltacabtagene autoleucel (cilta-cel), referred to as LCAR- B38M, is an autologous chimeric antigen receptor (CAR-T) cell therapy that targets the B-cell maturation antigen (BCMA), which is a highly expressed protein in several hematologic malignancies, including multiple myeloma (MM). In addition to cilta-cel, the Company has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, small cell lung cancer, and non-small cell lung cancer. It is also engaged in developing an allogeneic gamma delta CAR-T product candidate and an allogeneic CAR-NK product candidate targeting BCMA for MM.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Legend Biotech Launches $225 Million Public Offering
- Offering Size: Legend Biotech has announced the commencement of a $225 million public offering of American Depositary Shares (ADSs), all of which will be offered by the company, reflecting its proactive fundraising strategy in the capital markets.
- Underwriter Selection: Morgan Stanley, Jefferies, Citigroup, and Deutsche Bank Securities are serving as joint book-running managers for the offering, indicating the company's high standards and trust in the market when selecting underwriters.
- Additional Option: The company intends to grant underwriters a 30-day option to purchase up to an additional 15% of the ADSs, enhancing the offering's flexibility and potential fundraising capacity.
- Market Condition Impact: The offering is subject to market conditions, and while uncertainties exist, the company is committed to leveraging this financing to advance CAR-T cell therapy development, thereby strengthening its leadership position in cancer treatment.
See More
Legend Biotech Prices Public Offering of ADSs
- Offering Size: Legend Biotech has priced its public offering of 7,700,000 American Depositary Shares (ADSs) at $29.35 each, aiming for gross proceeds of approximately $226 million, reflecting strong market demand for its cell therapies.
- Underwriter Selection: Morgan Stanley, Jefferies, Citigroup, and Deutsche Bank are serving as joint book-running managers for the offering, indicating the company's credibility and attractiveness in the capital markets, further solidifying its leadership in the cell therapy sector.
- Additional Option: The company has granted underwriters a 30-day option to purchase an additional 1,155,000 ADSs at the same price, a strategy that could enhance total fundraising and increase financial flexibility.
- Market Outlook: The offering is expected to close on June 23, 2026, and if successful, will provide funding for Legend Biotech's future innovations and expansions, supporting its ongoing development in the CAR-T cell therapy space.
See More
Legend Biotech Launches $225 Million Public Offering of ADS
- Offering Size: Legend Biotech has commenced an underwritten public offering of $225 million in American depositary shares (ADS), with each ADS representing two ordinary shares, indicating the company's need for capital in the market.
- Underwriters' Option: The company plans to grant underwriters a 30-day option to purchase up to 15% additional ADSs, which, if fully exercised, could increase the total offering size beyond $225 million, thereby providing more financial support for the company.
- Market Reaction: Following the announcement of the public offering, Legend Biotech's shares fell 6% in after-hours trading, reflecting a cautious market sentiment regarding the offering, which may impact investor confidence.
- Industry Context: This offering occurs against the backdrop of the Federal Reserve's hawkish monetary policy, raising concerns about valuations in tech and biotech stocks, potentially leading to reduced demand for new stock issuances.
See More
LB2501 Shows Significant Efficacy in B-NHL Patients
- Clinical Trial Results: In an ongoing Phase 1 study, LB2501 achieved a 100% objective response rate (ORR) and an 83.3% complete response rate (CR) in patients with relapsed/refractory B-cell non-Hodgkin lymphoma, particularly notable in the high-dose cohort, indicating its therapeutic potential.
- Safety Profile: LB2501 demonstrated a favorable safety profile with no dose-limiting toxicities, serious adverse events, or deaths reported, while infusion-related reactions and cytokine release syndrome were all Grade 1-2, suggesting its acceptability for clinical use.
- Pharmacokinetic Characteristics: At the higher dose level, 100% of patients exhibited dose-dependent CAR-T cell expansion, with CAR-T cells detectable in peripheral blood for up to 116 days, supporting its feasibility as a next-generation cell therapy.
- Future Development Potential: These early clinical findings lay a foundation for further investigation of LB2501, reflecting the company's leadership in cell therapy and providing confidence for future commercialization and scientific advancements.
See More
Legend Biotech's LB2501 Shows Promising Data for Lymphoma Treatment
- Clinical Trial Results: Legend Biotech's LB2501 demonstrated promising preliminary data in treating B-cell non-Hodgkin lymphoma, achieving a 100% objective response rate and an 83.3% complete response rate among 12 patients, indicating significant efficacy that could transform treatment paradigms for B-cell malignancies.
- Strong Market Reaction: Following the data release, LEGN's stock surged over 42% on Tuesday, closing at $36.28, reflecting investor confidence in the therapy's prospects and highlighting the market's keen interest in biopharmaceutical innovations.
- Innovative Treatment Mechanism: LB2501 is a CD19/CD20 dual-targeting in vivo CAR-T cell therapy that generates CAR-T cells through a single intravenous infusion, eliminating the need for cell manufacturing and lymphodepletion, which may enhance patient convenience and acceptance of the treatment.
- Good Safety Profile: In the ongoing open-label Phase 1 study, no dose-limiting toxicities or serious adverse events were reported, and while 75% of patients experienced infusion-related reactions, all were recorded at Grade 2 severity or lower, demonstrating LB2501's favorable safety profile and enhancing its clinical applicability.
See More
Bluejay Diagnostics Partners with Argonaut, Shares Surge 100%
- Bluejay Partnership: Bluejay Diagnostics Inc. (BJDX) has entered a strategic partnership with Argonaut Manufacturing Services to advance its Symphony platform, leading to a 100% surge in share price to $4.34 on Tuesday, reflecting strong market confidence in its innovative diagnostic technology.
- Device Advantages: The Symphony platform can provide highly sensitive test results using just three drops of blood in about 20 minutes without additional reagents or sample preparation, significantly enhancing the simplicity and efficiency of clinical laboratory testing, which is expected to transform diagnostic practices in critical care.
- Picard Medical Progress: Picard Medical Inc. (PMI) successfully completed animal implant studies for its next-generation artificial heart platform at the University of Arizona, resulting in a 60.33% increase in share price, showcasing its technological advancements and market potential in cardiac treatment.
- Clinical Data Highlights: Legend Biotech Corp. (LEGN) will present promising preliminary Phase 1 data for LB2501 targeting relapsed/refractory B-cell non-Hodgkin lymphoma at the upcoming European Hematology Association Congress, demonstrating a 100% objective response rate, further solidifying its competitive position in the biopharmaceutical sector.
See More
Legend Biotech Launches $225 Million Public Offering
- Offering Size: Legend Biotech has announced the commencement of a $225 million public offering of American Depositary Shares (ADSs), all of which will be offered by the company, reflecting its proactive fundraising strategy in the capital markets.
- Underwriter Selection: Morgan Stanley, Jefferies, Citigroup, and Deutsche Bank Securities are serving as joint book-running managers for the offering, indicating the company's high standards and trust in the market when selecting underwriters.
- Additional Option: The company intends to grant underwriters a 30-day option to purchase up to an additional 15% of the ADSs, enhancing the offering's flexibility and potential fundraising capacity.
- Market Condition Impact: The offering is subject to market conditions, and while uncertainties exist, the company is committed to leveraging this financing to advance CAR-T cell therapy development, thereby strengthening its leadership position in cancer treatment.
See More
Legend Biotech Prices Public Offering of ADSs
- Offering Size: Legend Biotech has priced its public offering of 7,700,000 American Depositary Shares (ADSs) at $29.35 each, aiming for gross proceeds of approximately $226 million, reflecting strong market demand for its cell therapies.
- Underwriter Selection: Morgan Stanley, Jefferies, Citigroup, and Deutsche Bank are serving as joint book-running managers for the offering, indicating the company's credibility and attractiveness in the capital markets, further solidifying its leadership in the cell therapy sector.
- Additional Option: The company has granted underwriters a 30-day option to purchase an additional 1,155,000 ADSs at the same price, a strategy that could enhance total fundraising and increase financial flexibility.
- Market Outlook: The offering is expected to close on June 23, 2026, and if successful, will provide funding for Legend Biotech's future innovations and expansions, supporting its ongoing development in the CAR-T cell therapy space.
See More
Legend Biotech Launches $225 Million Public Offering of ADS
- Offering Size: Legend Biotech has commenced an underwritten public offering of $225 million in American depositary shares (ADS), with each ADS representing two ordinary shares, indicating the company's need for capital in the market.
- Underwriters' Option: The company plans to grant underwriters a 30-day option to purchase up to 15% additional ADSs, which, if fully exercised, could increase the total offering size beyond $225 million, thereby providing more financial support for the company.
- Market Reaction: Following the announcement of the public offering, Legend Biotech's shares fell 6% in after-hours trading, reflecting a cautious market sentiment regarding the offering, which may impact investor confidence.
- Industry Context: This offering occurs against the backdrop of the Federal Reserve's hawkish monetary policy, raising concerns about valuations in tech and biotech stocks, potentially leading to reduced demand for new stock issuances.
See More
LB2501 Shows Significant Efficacy in B-NHL Patients
- Clinical Trial Results: In an ongoing Phase 1 study, LB2501 achieved a 100% objective response rate (ORR) and an 83.3% complete response rate (CR) in patients with relapsed/refractory B-cell non-Hodgkin lymphoma, particularly notable in the high-dose cohort, indicating its therapeutic potential.
- Safety Profile: LB2501 demonstrated a favorable safety profile with no dose-limiting toxicities, serious adverse events, or deaths reported, while infusion-related reactions and cytokine release syndrome were all Grade 1-2, suggesting its acceptability for clinical use.
- Pharmacokinetic Characteristics: At the higher dose level, 100% of patients exhibited dose-dependent CAR-T cell expansion, with CAR-T cells detectable in peripheral blood for up to 116 days, supporting its feasibility as a next-generation cell therapy.
- Future Development Potential: These early clinical findings lay a foundation for further investigation of LB2501, reflecting the company's leadership in cell therapy and providing confidence for future commercialization and scientific advancements.
See More
Legend Biotech's LB2501 Shows Promising Data for Lymphoma Treatment
- Clinical Trial Results: Legend Biotech's LB2501 demonstrated promising preliminary data in treating B-cell non-Hodgkin lymphoma, achieving a 100% objective response rate and an 83.3% complete response rate among 12 patients, indicating significant efficacy that could transform treatment paradigms for B-cell malignancies.
- Strong Market Reaction: Following the data release, LEGN's stock surged over 42% on Tuesday, closing at $36.28, reflecting investor confidence in the therapy's prospects and highlighting the market's keen interest in biopharmaceutical innovations.
- Innovative Treatment Mechanism: LB2501 is a CD19/CD20 dual-targeting in vivo CAR-T cell therapy that generates CAR-T cells through a single intravenous infusion, eliminating the need for cell manufacturing and lymphodepletion, which may enhance patient convenience and acceptance of the treatment.
- Good Safety Profile: In the ongoing open-label Phase 1 study, no dose-limiting toxicities or serious adverse events were reported, and while 75% of patients experienced infusion-related reactions, all were recorded at Grade 2 severity or lower, demonstrating LB2501's favorable safety profile and enhancing its clinical applicability.
See More
Bluejay Diagnostics Partners with Argonaut, Shares Surge 100%
- Bluejay Partnership: Bluejay Diagnostics Inc. (BJDX) has entered a strategic partnership with Argonaut Manufacturing Services to advance its Symphony platform, leading to a 100% surge in share price to $4.34 on Tuesday, reflecting strong market confidence in its innovative diagnostic technology.
- Device Advantages: The Symphony platform can provide highly sensitive test results using just three drops of blood in about 20 minutes without additional reagents or sample preparation, significantly enhancing the simplicity and efficiency of clinical laboratory testing, which is expected to transform diagnostic practices in critical care.
- Picard Medical Progress: Picard Medical Inc. (PMI) successfully completed animal implant studies for its next-generation artificial heart platform at the University of Arizona, resulting in a 60.33% increase in share price, showcasing its technological advancements and market potential in cardiac treatment.
- Clinical Data Highlights: Legend Biotech Corp. (LEGN) will present promising preliminary Phase 1 data for LB2501 targeting relapsed/refractory B-cell non-Hodgkin lymphoma at the upcoming European Hematology Association Congress, demonstrating a 100% objective response rate, further solidifying its competitive position in the biopharmaceutical sector.
See More
